Page Content APHL collaborates with CDC to assure proficiency and quality of newborn screening test results at state public health laboratories, through emergency coordination, policy guidance and improvements to information exchange processes. In partnership with APHL, CDC's Newborn Screening Molecular Biology Branch (NSMBB) operates a voluntary, non-regulatory program to maintain and enhance the quality of newborn test results at state public health laboratories. The Newborn Screening Quality Assurance Program (NSQAP) provides services to more than 670 newborn screening laboratories around the world (including the US), 32 manufacturers of diagnostic products and laboratories in more than 86 countries. NSQAP is the only comprehensive source of dried blood spot reference materials in the US. The NSQAP sends coded specimens to participating laboratories to assess their testing proficiency. If a laboratory makes an error in identification, the program works with the institution to identify the error and improve laboratory practices. The program also publishes quarterly reports to allow laboratories to benchmark practices against their peers. Newborn Screening Analyte Interference List The Newborn Screening Analyte Interference List is a compilation of published and observed analyte interferences of newborn screening assays. The list serves as a central, one-stop resource for all known newborn screening assay interferences. Users can both review and add interferences to the list. Cutoff Determinations and Risk Assessment Methods The Overview of Cutoff Determinations and Risk Assessment Methods used in Dried Blood Spot Newborn Screening - Role of Cutoffs and Other Methods of Data Analysis provides a general overview of the variety of approaches utilized by newborn screening laboratories and program staff to determine if a newborn is at risk for a screened disorder. Webinars Congenital Hypothroidism (CH)Legacy Conditions Revisited: Newborn Screening for Congenital Hypothyroidism and Presentation Slides Mucopolysaccharidosis type II (MPS II) First-Tier Screening Methodologies for Mucopolysaccharidosis type II (MPS II) Spinal Muscular Atrophy (SMA) Clinical Aspects, Diagnostics and Follow-Up Recording and Transcript Overview of Available Screening Methods Recording and Transcript Mucopolysaccharidosis type I (MPS I) Implementation Considerations Webinar Recording and Transcript Clinical Aspects Webinar Recording and Transcript Overview of Available Screening Methods Webinar Recording and Transcript Unsatisfactory SpecimensUnsatisfactory Specimens: Interpretations, Studies and Current Trends Recording and Presentation It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.